Valuation: Akeso, Inc.

Capitalization 83B 93.68B 11.99B 10.07B 9.21B 8.77B 16.27B 1,087B 16.92B 107B 42.4B 523B 44.96B 44.04B 1,871B P/E ratio 2025 *
-308x
P/E ratio 2026 * 111x
Enterprise value 79.69B 89.95B 11.51B 9.67B 8.84B 8.42B 15.63B 1,044B 16.24B 103B 40.71B 502B 43.17B 42.29B 1,796B EV / Sales 2025 *
24.2x
EV / Sales 2026 * 14.9x
Free-Float
74.46%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
02-06 Akeso, Inc. Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer CI
02-03 Akeso granted exclusive commercialization rights for ebronucimab injection to Jumpcan Pharmaceutical RE
02-03 Akeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit MT
01-29 Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy CI
01-19 Akeso, Inc. Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis CI
01-14 Akeso, Inc. Announces Presentation of Real-World Study At the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium CI
01-12 Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC CI
01-07 Akeso, Inc. Announces the National Medical Products Administration Approves Significant Label Update in China for its Internally Develop, PD-1/VEGF Bispecific Antibody, ivonescimab CI
12-12 Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab CI
12-11 Akeso, Inc. Announces Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented atESMO IO 2025 CI
12-09 Akeso, Inc. Announces Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia Congress CI
12-09 Akeso, Inc. Announces Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia CI
11-17 Akeso, Inc.'s Bispecific Antibody Targeting Aß and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China CI
More news
1 day+3.93%
1 week+4.76%
Current month-4.26%
1 month-16.18%
3 months-8.17%
6 months-34.27%
Current year-6.46%
More quotes
1 week 98
Extreme 98
106.8
1 month 98
Extreme 98
130.1
Current year 98
Extreme 98
130.5
1 year 55.65
Extreme 55.65
179
3 years 26.45
Extreme 26.45
179
5 years 11.5
Extreme 11.5
179
10 years 11.5
Extreme 11.5
179
More quotes
Manager TitleAgeSince
Corporate Officer/Principal 50 15/11/2019
Corporate Officer/Principal 57 15/11/2019
Chief Tech/Sci/R&D Officer 58 15/11/2019
Director TitleAgeSince
Chairman 59 18/03/2012
Director/Board Member 58 15/11/2019
Director/Board Member 57 15/11/2019
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+3.93%+4.76%+63.75%+137.53% 11.99B
-0.57%-2.92%+10.14%+100.23% 51.1B
+0.89%+5.90%+69.68%+8.08% 42.55B
-0.21%-2.88%+87.04%+653.73% 31.89B
+3.49%+1.34%-6.18%-21.49% 27.69B
+4.65%+8.22%+83.58%-38.00% 20.25B
+0.12%-7.77%+41.43%-28.32% 18.95B
+4.29%+8.86%+141.15% - 12.51B
+0.11%+2.66%+31.27%+150.00% 11.83B
-0.13%+6.47%-25.56%+503.63% 11.54B
Average +1.66%+0.89%+49.63%+162.82% 24.03B
Weighted average by Cap. +1.23%-0.06%+46.48%+147.73%
See all sector performances

Financials

2025 *2026 *
Net sales 3.29B 3.72B 476M 400M 365M 348M 646M 43.17B 672M 4.25B 1.68B 20.74B 1.78B 1.75B 74.26B 5.25B 5.93B 759M 638M 583M 555M 1.03B 68.85B 1.07B 6.78B 2.68B 33.09B 2.85B 2.79B 118B
Net income -258M -292M -37.32M -31.36M -28.66M -27.3M -50.66M -3.39B -52.66M -333M -132M -1.63B -140M -137M -5.82B 754M 851M 109M 91.46M 83.59M 79.64M 148M 9.87B 154M 973M 385M 4.75B 408M 400M 16.99B
Net Debt -3.3B -3.73B -477M -401M -366M -349M -647M -43.27B -673M -4.26B -1.69B -20.79B -1.79B -1.75B -74.43B -4.78B -5.4B -691M -581M -531M -506M -938M -62.69B -975M -6.18B -2.44B -30.13B -2.59B -2.54B -108B
More financial data * Estimated data
Logo Akeso, Inc.
Akeso Inc is an investment holding company mainly engaged in the research and development, production and commercialization of biopharmaceutical products. The Company is committed to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide. The Company's products mainly include cadonilimab (PD-1/CTLA-4), Ivonescimab (AK112, PD-1/VEGF), ANNIKO (penpulimab, PD-1), Ebronucimab (AK102, PCSK9) and ebdarokimab (AK101, IL-12/IL-23). The Company's products are principally used to treat tumors, autoimmune diseases, metabolic diseases, as well as neurodegenerative diseases. The Company principally conducts its businesses in Mainland China, the United States and other markets.
Employees
3,529
More about the company
Date Price Change Volume
10/02/26 105.70 $ +3.93% 5,847,200
09/02/26 101.70 $ +0.79% 4,891,132
06/02/26 100.90 $ -0.39% 8,280,878
05/02/26 101.30 $ -1.36% 4,313,574
04/02/26 102.70 $ +1.78% 7,104,589

Delayed Quote Hong Kong S.E., February 10, 2026 at 08:09 am

More quotes
Trader
Investor
Global
Quality
ESG MSCI
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
90.10CNY
Average target price
154.60CNY
Spread / Average Target
+71.58%
Consensus

Quarterly revenue - Rate of surprise